CASI Pharmaceuticals
US-based biopharmaceutical firm offering cost-effective, innovative oncology treatments and pharmaceuticals.
Founded
1991US-based biopharmaceutical firm offering cost-effective, innovative oncology treatments and pharmaceuticals.
Casi Pharmaceuticals is a US-based biopharmaceutical company focused on delivering high-quality, cost-effective pharmaceutical products and innovative oncology therapeutics. The company specializes in hematologic malignancies and other unmet medical needs. Casi Pharmaceuticals offers a robust pipeline of commercially available and clinical-stage drug candidates, continually acquiring assets to expand its portfolio. The firm is dedicated to exploring therapies that save patients' lives.
Among its key achievements, Casi Pharmaceuticals launched EVOMELA® in China as its first commercial product. This milestone underscores the company's commitment to expanding its global footprint and addressing critical healthcare needs. The firm's impact is significant in the oncology sector, providing essential treatments and advancing medical research. Casi Pharmaceuticals continues to grow its influence through strategic acquisitions and a strong focus on innovative therapeutic solutions.
Companies similar to CASI Pharmaceuticals include Karyopharm Therapeutics, CBA Pharma, Cullinan Oncology and Traws Pharma.
CASI Pharmaceuticals was founded in 1991.
CASI Pharmaceuticals' headquarters is located in Rockville, MD, US.
CASI Pharmaceuticals' most recent funding round was for $32.5M (USD) in March 2021.
As of Mar 24, 2021, CASI Pharmaceuticals has disclosed funding of $185.4M (USD). Undisclosed round amounts are excluded.
CASI Pharmaceuticals has 224 employees as of Feb 6, 2024.
Traws Pharma
